Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

Hematology/ Oncology and Stem Cell Therapy

Volumn 5, Issue 1, 2012, Pages 1-30

  Majhail, Navneet S ^a,b   Rizzo, J Douglas ^c   Lee, Stephanie J ^d   Aljurf, Mahmoud ^e   Atsuta, Yoshiko ^f   Bonfim, Carmem ^g   Burns, Linda J ^h   Chaudhri, Naeem ^e   Davies, Stella ⁱ   Okamoto, Shinichiro ^j   Seber, Adriana ^k   Socie, Gerard ^l   Szer, Jeff ^m   van Lint, Maria Teresa ⁿ   Wingard, John R ^o   Tichelli, Andre ^p  

^a NATIONAL MARROW DONOR PROGRAM   (United States)

^b Center for International Health   (United States)

^c Center for International Blood and Marrow Research   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l SAINT LOUIS HOSPITAL   (France)

^m ROYAL MELBOURNE HOSPITAL   (Australia)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^p UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; BUSULFAN; CALCINEURIN INHIBITOR; CALCIUM; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOSCARNET; IMMUNOGLOBULIN; IRON CHELATING AGENT; METHOTREXATE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID; VITAMIN D;

ADJUVANT THERAPY; AVASCULAR NECROSIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHIOLITIS OBLITERANS SYNDROME; CANCER SCREENING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATARACT; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONNECTIVE TISSUE DISEASE; CYTOMEGALOVIRUS INFECTION; ENDOCRINE DISEASE; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; GENITAL SYSTEM DISEASE; GLOMERULAR THROMBOSIS; GLOMERULOPATHY; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEMATOPOIETIC CELL TRANSPLANTATION; HEPATITIS C; HERPES ZOSTER; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IDIOPATHIC PNEUMONIA SYNDROME; IMMUNOGLOBULIN G DEFICIENCY; INFECTION; INFERTILITY; INTERSTITIAL NEPHRITIS; IRON OVERLOAD; JAW OSTEONECROSIS; KERATOCONJUNCTIVITIS; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; LIFESTYLE; LIVER DYSFUNCTION; LUNG TOXICITY; MENTAL DISEASE; METASTASIS; MOUTH CANCER; MOUTH DISEASE; MUCOSAL DISEASE; MUCOSAL HYPERTROPHY; MYOPATHY; OSTEOPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; REVIEW; SCREENING; SEXUAL DYSFUNCTION; SINOPULMONARY INFECTION; SJOEGREN SYNDROME; SKIN DISEASE; SOCIOECONOMICS; SURVIVAL TIME; SURVIVOR; VAGINA DISEASE; WHOLE BODY RADIATION;

EID: 84859044853     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2012.1     Document Type: Article

References (77)

1. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230-2239.
2. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784-3792.
3. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoieticcell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005;105:4215-4222.
4. Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28:1888-1895.
5. Martin PJ, Counts GW, Jr., Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011-1016.
6. Majhail NS, Bajorunaite R, Lazarus HM, et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol. 2009;147:129-139.
7. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12:138-151.
8. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/ CIBMTR/ASBMT). Bone Marrow Transplant. 2006;37:249-261.
9. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44:453-558.
10. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143-1238.
11. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44:521-526.
12. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170.
13. Machado CM, Martins TC, Colturato I, et al. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop Sao Paulo. 2009;51:309-324.
14. Gea-Banacloche J, Masur H, Arns da Cunha C, et al. Regionally limited or rare infections: prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:489-494.
15. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-1754.
16. Kim SK. Update on ocular graft versus host disease. Curr Opin Ophthalmol. 2006;17:344-348.
17. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100:415-419.
18. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graftversus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375-396.
19. Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. 2004;104:1898-1906.
20. Benyunes MC, Sullivan KM, Deeg HJ, et al. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys. 1995;32:661-670.
21. Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. Ann Intern Med. 1993;119:1175-1180.
22. Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig. 2011;15:127-139.
23. Pavletic SZ, Lee SJ, Socie G, Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant. 2006;38:645-651.
24. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stemcell transplantation: an international case-control study. Blood. 2005;105:3802-3811.
25. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316-322.
26. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1175-1183.
27. Holtta P, Alaluusua S, Saarinen-Pihkala UM, Peltola J, Hovi L. Agenesis and microdontia of permanent teeth as late adverse effects after stem cell transplantation in young children. Cancer. 2005;103:181-190.
28. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med. 2004;25:189-201.
29. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
30. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302:306-314.
31. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1072-1078.
32. Aleman BM, van den Belt-Dusebout, AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886.
33. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463-3471.
34. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant. 2001;28:101-103.
35. Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood. 2010;116:1197-1204.
36. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
37. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51:1450-1460.
38. Barshes NR, Myers GD, Lee D, et al. Liver transplantation for severe hepatic graft-versushost disease: an analysis of aggregate survival data. Liver Transpl. 2005;11:525-531.
39. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618-1624.
40. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant. 2008;41:997-1003.
41. Hingorani S. Chronic kidney disease in longterm survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006;17:1995-2005.
42. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer. 2008;113:1580-1587.
43. Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB. Chronic kidney disease in longterm survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007;39:223-229.
44. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005;23:6596-6606.
45. Herzberg PY, Heussner P, Mumm FH, et al. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:1707-1717.
46. Couriel DR, Beguelin GZ, Giralt S, et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant. 2002;30:543-546.
47. Grauer O, Wolff D, Bertz H, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graftversus-host disease. Brain. 2010;133:2852-2865.
48. McClune BL, Polgreen LE, Burmeister LA, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;46:1-9.
49. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a longterm follow-up. Blood. 2004;103:3635-3643.
50. Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant. 2008;41:393-398.
51. Savani BN, Donohue T, Kozanas E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:517-520.
52. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-1503.
53. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761.
54. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Jama. 2011;305:783-789.
55. McAvoy S, Baker KS, Mulrooney D, et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:1231-1236.
56. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol. 1997;97:865-870.
57. Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology. 2003;60:842-848.
58. de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry. 2000;68:36-40.
59. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol. 2009;2:583-601.
60. Sostak P, Padovan CS, Eigenbrod S, et al. Cerebral angiitis in four patients with chronic GVHD. Bone Marrow Transplant. 2010;45:1181-1188.
61. Booth-Jones M, Jacobsen PB, Ransom S, Soety E. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005;36:695-702.
62. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011;29:2397-2404.
63. Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002;118:58-66.
64. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood. 2009;113:306-308.
65. Ranke MB, Schwarze CP, Dopfer R, et al. Late effects after stem cell transplantation (SCT) in children--growth and hormones. Bone Marrow Transplant. 2005;35 Suppl 1:S77-81.
66. Sanders JE. Endocrine complications of highdose therapy with stem cell transplantation. Pediatr Transplant. 2004;8 Suppl 5:39-50.
67. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008:134-141.
68. Spinelli S, Chiodi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica. 2003;88:1163-1168.
69. Zantomio D, Grigg AP, MacGregor L, Panek-Hudson Y, Szer J, Ayton R. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant. 2006;38:567-572.
70. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015-2023.
71. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113:4992-5001.
72. Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011;17:157-166.
73. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001;358:271-276.
74. Child and Adolescent Recommendations. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/tfchildcat.htm (accessed 05/01/2011).
75. Recommendations for Adults. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/adultrec.htm (accessed 05/01/2011).
76. Screening for Osteoporosis, Topic Page. January 2011. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf/uspsoste.htm (accessed 08/01/2011)
77. 2008 Physical activity guidelines for Americans. US Department of Health and Human Services, www.health.gov (accessed 07/15/2011)